Davis Polk advised the underwriters in connection with the offering of $3 billion aggregate principal amount of 1.625% U.S. dollar bonds due January 22, 2025, issued by Her Majesty in…
Davis Polk advised the underwriters in connection with the offering of C$750 million aggregate principal amount of 2.65% bonds due February 5, 2025, issued by the Province of Ontario. The…
Davis Polk advised MSCI Inc. in connection with a Rule 144A/Regulation S offering of an additional $500 million aggregate principal amount of its 4.000% senior notes due 2029. The…
Davis Polk advised the underwriters in connection with the offering of $2.25 billion aggregate principal amount of 1.875% bonds due November 13, 2024, issued by the Province of Alberta.
The…
Davis Polk advised MSCI Inc. in connection with a Rule 144A/Regulation S offering of $500 million aggregate principal amount of its 4.000% senior notes due 2029. The notes are guaranteed by…
Davis Polk advised Charles River Laboratories International, Inc. in connection with its Rule 144A/Regulation S offering of $500 million aggregate principal amount of 4.250% senior notes…
Davis Polk advised the lead managers on an SEC-registered offering by TD Bank of (i) $1.15 billion aggregate principal amount of its 1.900% senior notes due 2022 and (ii) $350 million…
Davis Polk advised the underwriters in connection with the offering of $1.25 billion aggregate principal amount of 2.000% bonds due October 2, 2029 issued by the Province of Ontario.
The…
Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 2,303,030 shares of its common stock. The common stock is listed on the…
Davis Polk advised the underwriters in connection with the offering of $1.25 billion aggregate principal amount of 1.750% bonds due 2024, issued by the Province of British Columbia.
The…